SOURCES SOUGHT
R -- Suicide Prevention - Market Research
- Notice Date
- 5/21/2018
- Notice Type
- Synopsis
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of Veterans Affairs;Program Contracting Activity Central;6150 Oak Tree Blvd, Suite 300;Independence OH 44131
- ZIP Code
- 44131
- Solicitation Number
- 36C77618Q9148
- Response Due
- 6/18/2018
- Archive Date
- 8/17/2018
- Point of Contact
- Andrea.Fink@va.gov
- Small Business Set-Aside
- N/A
- Description
- SUICIDE PREVENTION MARKET RESEARCH INTRODUCTION The U.S. Department of Veterans Affairs ( VA or Government ) Veterans Health Administration ("VHA") is considering new approaches to enhance Veteran well-being and engage the private sector to strengthen its ability to provide innovative health care treatments to Veterans. VA is conducting this Request for Information (RFI) to obtain information from external stakeholders (private sector), internal stakeholders (stakeholders internal to or already working with VA), and other innovators (respondents) who are potentially interested in partnering with VA. VA will use the information submitted in response to this RFI for planning purposes and for making strategic decisions regarding the exploration of innovative therapies. The VHA continues to meet Veterans' changing health care needs. Emerging treatments may provide hope and relief to Veterans who have tried and not found success with standard treatment approaches. The mission of the VHA Center for Compassionate Care Innovation (CCI) is to explore emerging therapies that are safe and ethical to enhance Veteran physical and mental well-being when other treatments have not been successful. CCI focuses on health concerns such as suicidality, traumatic brain injury, posttraumatic stress, and chronic pain. CCI explores innovations in a clinical context, not under the umbrella of medical research, to better understand the clinical implementation of health care innovations. CCI is interested in innovations that are safe, are aligned with VA s mission, and are capable of being implemented within VHA s healthcare system. More information about CCI is available at https://www.va.gov/HEALTHPARTNERSHIPS/CCISubmitaProposal.asp. The information gained from this RFI may lead to the exploration of additional treatments options for Veterans. VA will not enter into an agreement as a result of responses to this RFI. After review of the responses, CCI will determine if there is the breadth and depth of interest from Respondents to proceed with further discussions. VA/VHA/CCI reserves the right to consider, explore, and pursue innovations outside of and regardless of whether the innovations were submitted in response to this RFI. B. FOCUS ON SUICIDE PREVENTION It is CCI's intent to obtain information and open dialog with external and internal stakeholders interested in sharing details about health care innovations. The focus of this RFI is on the topic of suicidality and suicide prevention. Responses to this RFI should include an innovation in health care that is aimed to help reduce incidence of suicide, lower risk of suicide, and/or help prevent suicide, as well as reducing risk factors significantly correlated with suicide such as chronic pain, depression, and substance abuse. C. OBJECTIVES CCI is in the process of gathering information from internal and external stakeholders on treatments focused on reducing the risk and/or incidence of suicide, as well as reducing risk factors significantly correlated with suicide such as chronic pain, depression, and substance abuse. These innovations may already be available within VA but are not available broadly, or may not currently be available in VA. VHA will use this information to gain a better understanding of emerging therapies in the healthcare industry that support VA priorities, such as reducing the number of Veteran suicides. CCI seeks to satisfy the following objectives: Obtain a brief summary of innovative health care treatments or practices that address suicide in the Veteran population. Obtain written responses to the RFI questions listed in Section D. All questions, comments, and clarifications shall be submitted to the response Points of Contact by the response due date. D. TECHNICAL QUESTIONS Describe the innovation. (max 500 words) Briefly summarize the innovation (max 150 characters). Describe the type of innovation (e.g. Clinical Intervention/Treatment, Diagnostic, Educational, etc) Does it involve the use of technology? If so, please describe. How does the innovation facilitate suicide prevention? (i.e. Is it aimed to help reduce risk of suicide? Or help in times of crisis? Predict? Intervene?) What makes it innovative? What symptoms or conditions, if any, does the treatment target (ex: chronic pain, depression, substance abuse) Please describe any known or potential risks or side effects associated with the intervention. What is the cost of the innovation? Include context (ex: per person, per unit, per visit). Is the treatment appropriate for all Veterans or a sub population of Veterans (ex: Veterans with chronic pain, Veterans with a history of suicide attempt)? List any eligibility criteria or contraindications. Does the treatment require a trained administrator? What kind of clinical supervision is required? Is the innovation only available in a hospital setting? Can it be used in the home or other setting? Is the innovation intended to be used inside of healthcare, such as in a treatment plan? Or, is the innovation intended to be used outside of healthcare (ex: community or social support resources). Does the innovation need to be integrated with a patient s electronic health record (EHR)? Does the innovation collect protected health information (PHI)? Is the innovation compliant with the Health Insurance Portability and Accountability Act (HIPAA)? Supporting Evidence and Review Is there published scientific literature on this innovation? If so, please cite the reference(s). Please indicate if any of the research was conducted independently. Have there been clinical trials conducted using this innovation as an intervention? Please indicate if any of the clinical trials were conducted independently. If applicable, is the innovation FDA cleared/approved? If so, please describe the category the innovation is approved under (e.g. class, type) and provide any number associated with the approval (ex: 501(k) number). If applicable, is the innovation patented? If so, please provide the patent number. Availability within VA (max 150 words) Is the innovation already available within the VHA system? If so, where? If not, why would it be important for the VA to adopt this innovation? If the innovation is not already available in VA, how quickly do you anticipate treatment can be made available? Is there a VA staff member familiar with the innovation? If so, please provide their contact information. Is the innovation already available for purchase within the VA network? Do you foresee any barriers in implementing the innovation in VA? Have you previously been in contact with any VA staff regarding your innovation? If so, please provide their contact information. Feasibility of implementation (max 150 words) In what geographic region(s) is the innovation available? Is the innovation currently available nation-wide? If the innovation is an app or piece of technology is the innovation compliant with VA s privacy and security requirements? Expected outcomes (max 250 words) What outcomes do patients report? Do you have any testimonials? Examples of success? How many people have used it? How widespread is its availability? How long is the treatment protocol (e.g. minutes, days, hours, number of visits)? When do you start to see improvements? How long does the treatment effect last? Respondent Information: Please provide the best point of contact for this innovation including their first and last name, phone number, and email address. Is the respondent a VA internal stakeholder or an external stakeholder? Is the innovation the product of a public, private, o non-profit business? If so, what is the name of the business/organization? E. SUBMITTAL INFORMATION: Respondents having first-hand knowledge of an innovative health care treatment that matches the focus of this RFI described in section B should submit a single spaced, 12-point font minimum, response to the technical questions listed in section D above. Please also submit a cover page which includes, at a minimum, the company s name, address, Dunn & Bradstreet (DUNS) number (if available), General Service Administration (GSA) contract number (if applicable), point-of-contact name, phone number, and e-mail address. Respondents shall provide clear and unambiguous evidence to substantiate any claims they make regarding the efficacy of their treatment. If the respondent is a company, please provide the company business size and status - (i.e., Large Business, Small Business, Service-Disabled Veteran Owned Small Business, Veteran Owned Small Business, Women-Owned Small Business, etc.) Any affiliate information (parent company, joint venture partners, potential teaming partners, and VA Mentor Protégé Program membership status), as well as the number of years in business should also be provided (if applicable). Responses to this RFI shall address all items listed in section D. The responses shall not exceed five pages (Page count does not include the cover page described in section E). Each page must be numbered and labeled with the company or respondent s name. It is requested that the above information be provided no later than Monday, June 18th, 2018, 4:00PM EST. Responses should be emailed to William Henkel at William.Henkel@va.gov. All email correspondence for this project must reference the RFI Number, Project Identifier and Project Title in the subject line of the email. No phone calls will be accepted. RESULTS INFORMATION: Responses to this RFI will not be returned; neither will Respondents be notified of the Government's evaluation of the information received. The Government may incorporate into future competitive solicitations; any information or comment resulting from this request that is determined to be useful. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted under this RFI. F. DISCLAIMER In accordance with Federal Acquisition Regulation (FAR) 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any other kind of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. The Government shall not be liable for or suffer any consequential damages for any proprietary information not properly identified. Propriety information will be safeguarded in accordance with applicable Government Regulations. Proprietary information or trade secrets should be clearly identified. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked Proprietary will be handled accordingly. Responses to the RFI will not be returned. At this time, questions concerning the composition and requirements for future RFPs will not be entertained. NOTE: THIS NOTICE WAS NOT POSTED TO FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (21-MAY-2018); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link To Document
(https://www.fbo.gov/spg/VA/ISC/OISC/36C77618Q9148/listing.html)
- Record
- SN04928839-F 20180523/180522062901 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |